Search results for " Basic"

showing 10 items of 10515 documents

The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm

2017

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BCholestasisHepatologybusiness.industryABCB4Gastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineInternal medicineRealmHumansMedicine030211 gastroenterology & hepatologyIn patientbusinessHepatic fibrosisHepatology
researchProduct

Increased incidence or recurrence of hepatocellular carcinoma in hepatitis C virus cirrhotic patients treated with direct-acting antivirals: myth or …

2018

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusDIRECT ACTING ANTIVIRALSmedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansPharmacology (medical)business.industryIncidenceIncidence (epidemiology)Liver Neoplasmsmedicine.diseaseHepatitis CTreatment Outcome030104 developmental biologyOncologyHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessExpert Review of Anticancer Therapy
researchProduct

Reply to: “Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease”

2018

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyCirrhosisHepatologyPlatelet Countbusiness.industryNon invasiveFatty liverNon alcoholicDiseaseEsophageal and Gastric Varicesmedicine.diseaseGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineHumansMedicine030211 gastroenterology & hepatologyIn patientbusinessVaricesJournal of Hepatology
researchProduct

Editorial: covert hepatic encephalopathy-silent but serious. Authors’ reply

2018

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineCovertHepatic EncephalopathyQuality of LifemedicineHumans030211 gastroenterology & hepatologyPharmacology (medical)Prospective StudiesSleepIntensive care medicinebusinessHepatic encephalopathyAlimentary Pharmacology & Therapeutics
researchProduct

New clinical and pathophysiological perspectives defining the trajectory of cirrhosis

2021

Traditionally, the complications of cirrhosis, namely variceal bleeding, ascites and hepatic encephalopathy, were thought to result predominantly from circulatory dysfunction and altered organ perfusion arising as a result of portal hypertension. Over the past 20 years, large, international prospective studies have indicated the importance of systemic inflammation and organ immunopathology as additional determinants of organ dysfunction in cirrhosis, which not only manifests in the liver, brain, circulation and the kidneys, but also the immune system, gut, muscles, adrenal glands, reproductive organs, heart and lungs. This review provides an overview of the traditional and emerging concepts…

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyVaricesCirrhosisSystemic inflammationImmune System Phenomena03 medical and health sciences0302 clinical medicineImmunopathologyAscitesmedicineAcute on chronic liver failureHumansDecompensationIntensive care medicineHepatic encephalopathyHepatic encephalopathyInflammationHepatologybusiness.industryResearchOrgan dysfunctionGastroenterologyAscitesAcute on chronic liver failure; Ascites; Cirrhosis; Hepatic encephalopathy; Infection; Inflammation; Varicesmedicine.disease030104 developmental biologyCirrhosisDisease ProgressionPortal hypertension030211 gastroenterology & hepatologymedicine.symptombusinessInfection
researchProduct

Inflammasomes in Liver Fibrosis

2017

AbstractCell death and inflammation are two central elements in the development of liver fibrosis. Inflammasomes are intracellular multiprotein complexes expressed in both hepatocytes and nonparenchymal cells in the liver that are key regulators of inflammation and cell fate. They respond to cellular danger signals by activating caspase 1, releasing the proinflammatory cytokines IL-1β and IL-18, as well as initiating a novel pathway of programmed cell death termed “pyroptosis.” These processes can initiate and perpetuate an abnormal wound-healing response with the principle cellular target being the activation of hepatic stellate cells. From the various inflammasomes, the NLRP3 inflammasome…

Liver Cirrhosis0301 basic medicinemedicine.medical_treatmentAnti-Inflammatory AgentsCaspase 1BiologyLiver transplantationProinflammatory cytokine03 medical and health sciencesLiver diseaseFibrosisNLR Family Pyrin Domain-Containing 3 ProteinPyroptosismedicineAlarminsAnimalsHumansHepatologyPyroptosisInflammasomemedicine.disease030104 developmental biologyReceptors Pattern RecognitionImmunologyHepatic stellate cellInflammation MediatorsSignal Transductionmedicine.drugSeminars in Liver Disease
researchProduct

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.

2021

[BACKGROUND & AIMS] Primary biliary cholangitis (PBC) is a chronic liver disease in which autoimmune destruction of the small intra-hepatic bile ducts eventually leads to cirrhosis. Many patients have inadequate response to licensed medications, motivating the search for novel therapies. Previous genome-wide association studies (GWAS) and meta-analyses (GWMA) of PBC have identified numerous risk loci for this condition, providing insight into its aetiology. We undertook the largest GWMA of PBC to date, aiming to identify additional risk loci and prioritise candidate genes for in silico drug efficacy screening. [METHODS] We combined new and existing genotype data for 10, 516 cases and 20, 77…

Liver CirrhosisALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC0301 basic medicineCandidate geneALSPAC; ERN RARE-LIVER; Genomic co-localization; Network-based in silico drug efficacy screening; UK-PBC; Genome-Wide Association Study; Humans; Liver Cirrhosis BiliaryItalian PBC Study GroupLD SCORE REGRESSIONJapan-PBC-GWAS ConsortiumGenome-wide association studyLocus (genetics)DiseaseSUSCEPTIBILITYPBCChronic liver diseaseBioinformaticsGENETIC ASSOCIATION1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineUK-PBC ConsortiumGenotypeHumansMedicineNetwork-based in silico drug efficacy screeningGenetic associationScience & TechnologyGastroenterology & HepatologyHepatologyLiver Cirrhosis Biliarybusiness.industryBiliaryChinese PBC Consortium1103 Clinical SciencesALSPACmedicine.diseasePBC Consortia030104 developmental biologyMeta-analysisERN RARE LIVER030211 gastroenterology & hepatologyGenomic co-localizationUK-PBCUS PBC ConsortiumERN RARE-LIVERCanadian PBC ConsortiumbusinessLife Sciences & BiomedicineGenome-Wide Association StudyHuman
researchProduct

Exploring organ-specific features of fibrogenesis using murine precision-cut tissue slices

2019

Fibrosis is the hallmark of pathologic tissue remodelling in most chronic diseases. Despite advances in our understanding of the mechanisms of fibrosis, it remains uncured. Fibrogenic processes share conserved core cellular and molecular pathways across organs. In this study, we aimed to elucidate shared and organ-specific features of fibrosis using murine precision-cut tissue slices (PCTS) prepared from small intestine, liver and kidneys. PCTS displayed substantial differences in their baseline gene expression profiles: 70% of the extracellular matrix (ECM)-related genes were differentially expressed across the organs. Culture for 48 h induced significant changes in ECM regulation and trig…

Liver CirrhosisEXPRESSION0301 basic medicineINHIBITOR LY2157299 MONOHYDRATEPROTEINPrecision-cut tissue slicesSmad2 ProteinLIVER FIBROSISBiologyKidneyMECHANISMSSMAD2ACTIVATIONPATHWAYExtracellular matrixMiceTGFβ03 medical and health sciences0302 clinical medicineTransforming Growth Factor betaTGF betaFibrosisGene expressionTGF beta signaling pathwaymedicineAnimalsGalunisertibProtein Kinase InhibitorsMolecular BiologyMOLECULAR CHAPERONEGROWTH-FACTOR-BETAKinaseTGF-BETAExtracellular matrixmedicine.diseaseFibrosisPathophysiologyCell biologyMice Inbred C57BL030104 developmental biologyLiver030220 oncology & carcinogenesisQuinolinesPyrazolesMolecular MedicineCollagenHomeostasisSignal TransductionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct

Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation

2019

Background & Aims Alpha-1 antitrypsin deficiency (AATD) is among the most common genetic disorders. Severe AATD is caused by a homozygous mutation in the SERPINA1 gene that encodes the Glu342Lys substitution (called the Pi*Z mutation, Pi*ZZ genotype). Pi*ZZ carriers may develop lung and liver diseases. Mutation-associated lung disorders have been well studied, but less is known about the effects in liver. We assessed the liver disease burden and associated features in adults with this form of AATD. Methods We collected data from 554 Pi*ZZ adults (403 in an exploratory cohort, 151 in a confirmatory cohort), in 9 European countries, with AATD who were homozygous for the Pi*Z mutation, and 234…

Liver CirrhosisMale0301 basic medicineALTLiver diseasechemistry.chemical_compound0302 clinical medicineLiver Function TestsRisk FactorsGenotypeRare Liver DiseaseAlpha 1-antitrypsin deficiencyHomozygoteAge FactorsGastroenterologyMiddle AgedEuropeEditorial CommentaryPhenotypemedicine.anatomical_structureLiverElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyTEAdultmedicine.medical_specialty610Mice Transgenic03 medical and health sciencesSex Factorsalpha 1-Antitrypsin DeficiencyInternal medicinemedicinePiAnimalsHumansGenetic Predisposition to DiseaseASTAgedLungHepatologyTriglyceridebusiness.industryLipid Metabolismmedicine.diseaseFatty Liver030104 developmental biologyEndocrinologychemistryCase-Control Studiesalpha 1-AntitrypsinMutationSteatosisTransient elastographybusinessGastroenterology
researchProduct

Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis

2016

AIM. To evaluate the effects of asymmetric dimethylarginine (ADMA) in renal arteries from portal hypertensive and cirrhotic rats. METHODS. Rat renal arteries from Sham (n = 15), pre-hepatic portal hypertension (PPVL; n = 15) and bile duct ligation and excision-induced cirrhosis (BDL; n = 15) were precontracted with norepinephrine, and additional contractions were induced with ADMA (10-6-10-3 mol/L), an endogenous inhibitor of nitric oxide (NO) synthase. Concentration-response curves to acetylcholine (1 × 10-9-3 × 10-6 mol/L) were determined in precontracted renal artery segments with norepinephrine in the absence and in the presence of ADMA. Kidneys were collected to determine the protein e…

Liver CirrhosisMale0301 basic medicineAsymmetric dimethylarginineCirrhosisArginineKidneyurologic and male genital diseasesRats Sprague-DawleyNorepinephrinechemistry.chemical_compoundRenal ArteryVasoconstrictor AgentsEnzyme InhibitorsPortal hypertensionKidneyGastroenterologyGeneral MedicineBasic StudyDimethylarginine dimethylaminohydrolaseNG-Nitroarginine Methyl Estermedicine.anatomical_structureCirrhosisCardiologyPortal hypertensionmedicine.symptommedicine.medical_specialtyCirrosi hepàticaEndotheliumArginineNitric OxidePressió sanguíniaAmidohydrolases03 medical and health sciencesInternal medicinemedicine.arteryHypertension PortalmedicineAnimalsHumansEndotheliumRenal arterybusiness.industrymedicine.diseaseAcetylcholineRats030104 developmental biologychemistryVasoconstrictionNitric oxide inhibitorsNitric Oxide SynthaseAsymmetric dimethylargininebusinessVasoconstriction
researchProduct